Author: Kathryn Atkins

Prognostic and Therapeutic Insights Into MIF, DDT, and CD74 in Melanoma

July 26, 2024

“[...] we present the first study to retrospectively evaluate differential gene expression of MIF, DDT, and relevant pathway markers in regard to clinical outcomes in patients with melanoma.” BUFFALO, NY-… read more

Oncotarget

Prevalence and Impact of the KIT M541L Variant in Patients With Mastocytosis

July 24, 2024

“This study uniquely examines the prevalence and impact of the KIT M541L variant in both adult and pediatric patients with mastocytosis further stratified by disease variant.” BUFFALO, NY- July 24,… read more

Oncotarget

Oncotarget Welcomes New Editorial Board Members

July 22, 2024

Oncotarget is also offering a 50% discount on publication fees until the end of the year. BUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our… read more

Oncotarget

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC

July 22, 2024

“Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.” BUFFALO, NY-… read more

Oncotarget

DDX41 and Its Unique Contribution to Myeloid Leukemogenesis

July 19, 2024

“[...] myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.” BUFFALO, NY- July 19, 2024 – A new editorial… read more

Oncotarget

Using Early On-treatment Circulating Tumor DNA Measurements as Response Assessment in Metastatic Castration Resistant Prostate Cancer

July 17, 2024

“[...] results of Tolmeijer et al. show the promise of on-treatment ctDNA detection as early read out for treatment response to potentially help guide treatment management of patients with mCRPC.”… read more

Oncotarget

HER2-low and HER2-zero in Breast Cancer Between Prognosis, Prediction and Entity

July 16, 2024

“[...] we found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer.” BUFFALO, NY- July 16, 2024 – A new editorial paper was published in… read more

Oncotarget

Comparison of FDG-PET/CT and CT for Treatment Evaluation of Patients With Unresectable Malignant Pleural Mesothelioma

July 15, 2024

“FDG-PET is generally considered as a useful metabolic evaluation tool, while it is also thought to have an emerging role for assessment of systemic therapy response.” BUFFALO, NY- July 15,… read more

Oncotarget

Targeting ABC Transporters in PDAC – Past, Present, or Future?

July 10, 2024

“[...] it is crucial for the future application of ABC transporter inhibitors [...] to develop a stratification protocol [...] to identify those PDAC patients who are most likely to benefit… read more

Figure 5: TAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling.

Oncotarget

Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers

July 8, 2024

“In this study, we investigated the therapeutic effects and the underlying mechanisms of TAS-102 in combination with regorafenib against gastrointestinal cancers.” BUFFALO, NY- July 8, 2024 – A new research… read more